Clinical Trial Update: Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating cemiplimab in combination with fianlimab for patients with resectable non-metastatic colon cancer; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)
• Fianlimab (fianlimab)

Snippet

Sponsor: John Strickler, M.D. | Conditions: Colon Cancer | Phase 2 | Status: NOT_YET_RECRUITING